SAAT Healthcare Ltd, founded in 2016, is dedicated to the research and development of innovative healthcare solutions that address the specific needs of the aging population and the shifting landscape of patient-doctor consultations. With the increasing economic pressures on the NHS, SAAT Healthcare has focused its efforts on advancing home healthcare diagnostics. Their strategic focus is aimed at improving patient outcomes whilst reducing healthcare costs by enabling early detection and management of medical conditions, thereby minimising the need for hospital stays and extensive medical interventions.
SAAT identified four key health areas that are critical to public health and where early intervention can have the most significant impact: Sleep Apnoea and Sleep Disorders, Asthma, Cardiac Conditions, and COVID-19. These conditions were selected due to their prevalence and the serious health risks they pose, particularly to older adults. By concentrating on these areas, SAAT Healthcare aimed to create diagnostic tools that were not only effective but also accessible and easy to use in a home setting.
To advance its mission, SAAT Healthcare approached Optima to develop specialised respiratory equipment specifically targeting the Sleep Apnoea field. These devices were designed to integrate with specific apps, allowing patients to record and relay their health data to their GPs. This setup was intended to facilitate efficient and cost-effective virtual consultations, enabling healthcare providers to identify and address potential health issues early on, before they escalate into more serious conditions.
Leveraging SAAT Healthcare’s extensive research and expertise, Optima developed a range of product concepts tailored to home diagnostics and medical analysis. These included a sleep Apnoea analysis mask, an advanced thermometry device, and an innovative tool for monitoring the effectiveness of inhaled medications, designed to attach to standard asthma inhalers. These concepts were developed to a stage where they could be prototyped and tested rigorously. The brief also required the creation of test rigs, calibrated to mimic patient interactions, establishing the safety, validity and efficacy of the products before any costly live patient trials.
Dr Philip Stimpson, Chairman
Saat Healthcare Ltd